Options
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
42
Journal Issue
7
End Page
820
Date Issued
2024-03-01
Author(s)
Jänne, Pasi A
Planchard, David
Kobayashi, Kunihiko
Cheng, Ying
Lee, Chee Khoon
Valdiviezo, Natalia
Laktionov, Konstantin
Yang, Tsung-Ying
Yu, Yan
Kato, Terufumi
Jiang, Liyan
Chewaskulyong, Busyamas
Lucien Geater, Sarayut
Maurel, Jean-Marc
Rojas, Carlos
Takahashi, Toshiaki
Havel, Libor
Shepherd, Frances A
Tanaka, Kentaro
Ghiorghiu, Dana
Amin, Neha P
Armenteros-Monterroso, Elena
Huang, Xiangning
Chaudhry, Ammar Ahmed
Abstract
We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status.
Type
journal article